Fibrodysplasia Ossificans Progressiva
Fibrodysplasia Ossificans Progressiva (FOP) is a rare genetic disorder where soft tissues progressively turn into bone, leading to severe mobility restrictions and a characteristic pattern of bone formation.
Fibrodysplasia Ossificans Progressiva: Fidrisertib Study
We are studying a new oral medication for people with fibrodysplasia ossificans progressiva to see if it can help prevent new bone growth and improve overall health. This trial includes both children and adults to evaluate its safety and effectiveness.
Efficacy phase (II)Post-Trial Drug AccessCost ReimbursementPartially RemoteInvestigational MedicinesOralHematologyInternal MedicineNeurology
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you at least 5 years old?
- Do you have a diagnosis of Fibrodysplasia Ossificans Progressiva (FOP)?
- Have you had any new symptoms or flare-ups related to your condition in the past year, like swelling or pain?
- Are you currently pregnant or breastfeeding?
- Do you weigh at least 10 kg?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Tetrahydrofuran
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
UZ Leuven
Department of Neurology
Heverlee, Belgium
Assistance Publique Hopitaux De Paris
Service de Rhumatologie
Angers, France
Assistance Publique Hopitaux De Paris
Institut Imagine – Département de Génétique
Montrouge, France
Sponsor: Clementia Pharmaceuticals Inc. An Ipsen Company
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.